Genfit S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
12,652.10
17,025.50
17,135.00
33,667.00
58,604.00
79,521
Depreciation, Depletion & Amortization
474.50
292.10
327.00
630.00
1,412.00
1,819
Other Funds
143.40
1,047.00
2,248.00
132.00
683.00
4,938
Funds from Operations
9,716.50
15,686.40
14,560.00
33,169.00
56,509.00
72,764
Changes in Working Capital
391.70
96.50
297.00
5,900.00
5,281.00
10,332
Net Operating Cash Flow
9,324.80
15,589.90
14,857.00
27,269.00
51,228.00
62,432
Capital Expenditures
239.60
721.00
790.00
2,036.00
2,800.00
Sale of Fixed Assets & Businesses
8,045.80
15.00
2.00
-
15.00
Purchase/Sale of Investments
483.20
4,300.00
4,284.00
50.00
163.00
Net Investing Cash Flow
7,323.00
5,006.00
3,496.00
2,086.00
2,948.00
Issuance/Reduction of Debt, Net
3,295.30
749.40
802.00
466.00
155,722.00
Net Financing Cash Flow
16,625.90
71,632.70
533.00
121,523.00
175,720.00
Net Change in Cash
14,624.10
51,036.80
11,894.00
92,168.00
121,544.00
Free Cash Flow
9,564.40
16,310.90
15,647.00
29,305.00
54,028.00
Deferred Taxes & Investment Tax Credit
2,317.70
-
-
-
-
-
Change in Capital Stock
19,921.20
72,382.10
269.00
121,057.00
19,997.00

About Genfit

View Profile
Address
Parc Eurasante
Loos Nord-Pas-de-Calais 59120
France
Employees -
Website http://www.genfit.com
Updated 07/08/2019
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. Its research and development efforts are focused on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver.